Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination

Background Patients (Pts) with multiple myeloma (MM) experience prolonged immunosuppression due to the incurable nature of the disease and corresponding treatment modalities. Due to this many MM pts with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require hospitalization, with an in...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdallah, Al-Ola, Mahmoudjafari, Zahra, Mohan, Meera, McGuirk, Joseph P., Remker, Cassie, Foss, Margaret, Karloff, Ellie, Fitch, Heather, Mohyuddin, Ghulam Rehman, Atrash, Shebli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701577/
http://dx.doi.org/10.1182/blood-2021-152954

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701577/
http://dx.doi.org/10.1182/blood-2021-152954

Ejemplares similares